Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

elephone replay will be available through November 6, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non- nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598 and ANA773, including the trial design, occurrence, timing, and pace of future clinical trials, the timing for obtaining viral load data and expectations regarding such data, as well as the anticipated future clinical benefits of ANA598 and ANA773. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements. For example, the results of preclinical studies and early clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... (PRWEB) May 17, 2013 The new ... Photonics21 at the association’s recent annual meeting drew ... EC Vice-President Neelie Kroes, who called the action “a ... and a stimulant to European innovation.” , The Board ... of the new Photonics PPP at its 29 April ...
(Date:5/17/2013)...  Yongye International, Inc. (NASDAQ: YONG ) ... distributor of crop nutrient products in the ... on May 16, 2013, the special committee (the "Special ... Directors") was provided a letter (the "Letter") issued by ... Limited ("Abax") to Full Alliance International Limited ("Full Alliance"). ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 The paradigm ... complex biological systems that can help predict the adverse ... Dr. Sergey Stepaniants, Head of Computational Biology at the ... biology tools to ensure high-quality genomics when used as ... be applied to complex data sets to identify key ...
(Date:5/17/2013)... May 17, 2013 Tooth decay is an ... active signs of the disease. The World Health Organization says ... 100% of adults have cavities. What are the long-term effects ... showing a strong connection between the oral bacterial imbalance and ... disease so rampant, yet it is also 100% preventable? Answer: ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... , , RALEIGH, N.C. , ... the management and analysis of genetic data, today announced that it ... will utilize SmartGene,s advanced technology and integrated Web-based services to support ... sequence analysis. , , Some bacteria and fungi ...
... /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company ... on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today ... its vaccine candidate for the Influenza A (H1N1) virus, ... single dose of 5 micrograms induced a positive immune ...
... BETHESDA, Md., July 30 Micromet, Inc. (Nasdaq: ... antibodies for the treatment of cancer, inflammation and autoimmune diseases, ... shares of its common stock at a public offering price ... being offered by Micromet. The gross proceeds to Micromet, ...
Cached Biology Technology:SmartGene's Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital 2Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose 2Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose 3Micromet Announces Pricing of Public Offering of Common Stock 2Micromet Announces Pricing of Public Offering of Common Stock 3Micromet Announces Pricing of Public Offering of Common Stock 4
(Date:5/18/2013)... 2013) Research presented today at Digestive Disease Week ... findings about the impact of coffee on autoimmune disease ... coffee consumption recently has been associated with reduced risk ... few more cups of java each month also correlate ... Researchers at the Mayo Clinic, Rochester, MN, linked coffee ...
(Date:5/17/2013)... Researchers at Rutgers, The State University of New Jersey, ... proprietary new formulation called Visikol TM that effectively ... be used in place of chloral hydrate, which is ... but which is tightly regulated by the Drug Enforcement ... , Clearing solutions, or clearing agents, are vital for ...
(Date:5/17/2013)... College study finds human-caused climate change may have ... contradicting a host of recent studies that predict ... , The findings, which appear in the journal ... for survival of a creature thought to be ... tropical cold-blooded animals, especially forest lizards, will be ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3Climate change may have little impact on tropical lizards 2
... of Seville (Spain) have developed a technique based on ... beer. The content of iron, potassium, phosphates and polyphenols ... Portuguese beers have been detected with 99% accuracy thanks ... one another according to their country of origin by ...
... State University, the University of Washington and University of ... of prehistoric non-native animal remains in the Caribbean, on ... our understanding of culture in the region before the ... more important than previously thought. The researchers found ...
... Ariz. -- A son,s passion to find a cure for ... led to a new series of clinical trials under a ... for pancreatic cancer. The ,Seena I, clinical trial is ... who fell victim to pancreatic cancer the nation,s fourth ...
Cached Biology News:Where does my beer come from? 2Archaeologists find new evidence of animals being introduced to prehistoric Caribbean 2'Seena' clinical trials named for pancreatic cancer advocate 2'Seena' clinical trials named for pancreatic cancer advocate 3
... combine the proven features of the pET, ... provides all of the benefits and versatility ... backbone. The pTriEx vectors have been extensively ... in all three expression systems. In each ...
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
... Stem Cell Identification Kit. ... a substrate for the ... that is highly expressed ... cells, making ALDH an ...
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
Biology Products: